Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.

Urology - 1 Jan 2001

Nam R K, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett M A, Narod S A

Abstract excerpt

OBJECTIVES: The valine (V) to leucine (L) polymorphism of the SRD5A2 gene is associated with 5-alpha reductase-2 activity; patients with the V allele have high activity and patients with the L allele have low activity. We examined whether this polymorphism predicts the presence of prostate cancer in 320 men without cancer who underwent biopsy and cancer progression in 318 men who underwent radical prostatectomy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Follow-Up Studies
Share to Leucine
Share to Neoplasm Proteins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Recurrence, Local

Share to Odds Ratio

Share to Oxidoreductases

Share to Prostatic Neoplasms

Share to Valine

Source

Identifiers

PMID: 11164181
DOI: 10.1016/s0090-4295(00)00928-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.PMID 11164181Read ↗

SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.Semantic proximity Read ↗

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.Semantic proximity Read ↗

SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.Semantic proximity Read ↗

Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese population.Semantic proximity Read ↗

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.Semantic proximity Read ↗

Polymorphism of the SRD5A2 gene and the risk of prostate cancer.Semantic proximity Read ↗

Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.Semantic proximity Read ↗

Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.Semantic proximity Read ↗

V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.Semantic proximity Read ↗

SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.Semantic proximity Read ↗

The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer.Semantic proximity Read ↗

Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.